Aprea therapeutics presents preliminary findings on oral wee1 inhibitor apr-1051 at eortc-nci-aacr international conference on molecular targets and therapeutics

Phase 1 acesot-1051 clinical trial is evaluating apr-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the u.s.
APR Ratings Summary
APR Quant Ranking